| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_CDYL_0010000 | Intron-Exon-Intron | chr6:4935749-4939356 | chr6:4935515-4939122 | 225 nt | 0.4533 |
| hsa_CDYL_0010100 | Exon-Exon | chr6:4935749-4943990 | chr6:4935515-4943756 | 211 nt | 0.4360 |
| hsa_CDYL_0010300 | Exon-Exon | chr6:4935815-4943990 | chr6:4935581-4943756 | 575 nt | 0.4557 |
| hsa_CDYL_0010400 | Intron-Intron | chr6:4936462-4937714 | chr6:4936228-4937480 | 1253 nt | 0.4142 |
| hsa_CDYL_0010500 | Exon-Exon | chr6:4937799-4952643 | chr6:4937565-4952409 | 528 nt | 0.4924 |
A study in humans demonstrated that the circCDYL is highly expressed in early stages of hepatocellular carcinoma, bladder cancers, and breast cancer [Misir et al. DOI:10.1038/s41418-022-00948-7]. In hepatocellular carcinoma, it promotes stem-like characteristics and tumor growth via the miR-328-3p/HIF1AN axis under hypoxic conditions [Huang et al. DOI:10.3390/cells11091381]. A study in mice demonstrated that the circCDYL is decreased in myocardial tissues and hypoxia myocardial cells, where it improves cardiac function after acute myocardial infarction [Sema Misir et al. DOI:10.1038/s41418-022-00948-7].